Mira Pharmaceuticals Inc
MIRA
查看详细走势图
1.180USD
-0.020-1.67%
交易中 （美东）报价延迟15分钟
46.62M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-1.67%
5天
-4.84%
1月
-20.81%
6月
-14.49%
今年开始到现在
-21.85%
1年
+2.61%
查看详细走势图
TradingKey Mira Pharmaceuticals Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Mira Pharmaceuticals Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值低估，在生物技术与医疗研究行业排名229/392位。机构持股占比非常高，近一月多位分析师给出公司评级为。最高目标价3.00。中期看，股价处于下降通道。近一个月，市场表现非常差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Mira Pharmaceuticals Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Mira Pharmaceuticals Inc亮点
亮点风险
MIRA Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company's pipeline includes oral drug candidates designed to address significant unmet medical needs in neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. It holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2 and MIRA-55, two novel drug candidates designed to address unmet medical needs in neuropathic and inflammatory pain, as well as neuropsychiatric and neurocognitive disorders. Its pipeline also includes SKNY-1, a next-generation oral therapy candidate for obesity and smoking cessation. Ketamir-2 is a patent-pending oral ketamine analog evaluated for the treatment of diabetic neuropathy and is in an ongoing Phase I clinical trial.
估值高估
公司最新PE估值-0.75，处于3年历史高位
机构加仓
最新机构持股1.83M股，环比增加11.60%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值660.50K
活跃度降低
近期活跃度降低，过去20天平均换手率-0.86
分析师目标
根据
0
位分析师
--
评级
3.000
目标均价
+109.79%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Mira Pharmaceuticals Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Mira Pharmaceuticals Inc简介
MIRA Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company's pipeline includes oral drug candidates designed to address significant unmet medical needs in neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. It holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2 and MIRA-55, two novel drug candidates designed to address unmet medical needs in neuropathic and inflammatory pain, as well as neuropsychiatric and neurocognitive disorders. Its pipeline also includes SKNY-1, a next-generation oral therapy candidate for obesity and smoking cessation. Ketamir-2 is a patent-pending oral ketamine analog evaluated for the treatment of diabetic neuropathy and is in an ongoing Phase I clinical trial.
公司代码MIRA
公司Mira Pharmaceuticals Inc
CEOAminov (Erez)
网址https://mirapharmaceuticals.com/
相关品种
